WuXi XDC, a global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADCs and the other types of bioconjugates, and Celltrion, Inc., a global biopharmaceutical company, have signed a Memorandum of Understanding (MOU) for comprehensive and integrated services for the development and manufacturing of bioconjugates include antibody-drug conjugates (ADCs).
 
WuXi XDC will serve as primary service provider on each of the integrated projects, from process development to GMP manufacturing, within the global territory. WuXi XDC will support Celltrion’s pipeline providing comprehensive services from process development to GMP manufacturing.
 
Mr. Jong Moon Cho VP of Celltrion, said, “Celltrion is focused on fostering the innovation to answer the unmet needs and contribute to the sustainability of healthcare systems. WuXi XDC is an ideal partner for Celltrion given their advanced platform and broad expertise in ADC development and manufacturing. Collaborating with WuXi XDC provides an exciting opportunity for us to further accelerate our innovative pipeline development and benefit patients worldwide.” 
 
Dr. Jimmy Li, CEO of WuXi XDC, said, “We are very pleased to partner with Celltrion to accelerate their innovative pipeline. With our fully integrated, one-stop platform, we look forward to collaborating with Celltrion to expedite the development and manufacturing for ADC and other bioconjugate candidates. As a global CRDMO, we remain committed to enabling our clients to advance and grow innovative therapeutics at a fast speed and with high quality and supporting them to achieve the goal of benefiting patients worldwide in the coming years.”